FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. A conjugate of the receptor-binding domain (RBD) protein of the surface glycoprotein S of the SARS-CoV-2 virus, 308V-542N, is described for obtaining a vaccine complex against the coronavirus infection COVID-19, developed in CHO cells, having a length of 244 a.a., molecular weight of 35 kDa, the amino acid sequence of SEQ ID N 2 associated with the polymer polyglucin-spermidine (PGS) at a calculated ratio of RBD protein molecules and PGS molecules - 1:1. Also described is a vaccine complex against coronavirus infection COVID-19 in the form of nanoparticles that induce the formation of T-cell immunity and SARS-CoV-specific antibodies with virus-neutralizing activity, and consisting of polyglucin-spermidine-protein RBD conjugate molecules according to claim 1 and plasmid molecules pVAX-RBD DNA, with each nanoparticle having a size of at least 50 nanometers, contains a core consisting of pVAX-RBD plasmid DNA molecules and a polyglucin-spermidine-protein RBD conjugate layer located around the core, retained due to ionic interaction between the negatively charged core and the positively charged core. charged spermidine.
EFFECT: creation of a simpler immunogenic construct, which, when administered intramuscularly, is capable of inducing a high level of antibodies with virus-neutralizing activity, as well as providing a virus-specific T-cell response.
3 cl, 16 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PLASMID pVAX-RBD DNA MATRIX OF mRNA-RBD MOLECULES, OBTAINED USING THE pVAX - RBD DNA MATRIX, PROVIDING THE SYNTHESIS AND SECRETION OF THE RBD PROTEIN SARS-CoV 2 IN MAMMALIAN CELLS AND A COMPLEX IN THE FORM OF NANOPARTICLES CONTAINING mRNA-RBD MOLECULES THAT INDUCE SARS-CoV-SPECIFIC ANTIBODIES WITH VIRAL NEUTRALIZING ACTIVITY | 2021 |
|
RU2754230C1 |
| ARTIFICIAL GENE ENCODING THE BSI-COV-UB IMMUNOGEN PROTEIN, RECOMBINANT PLASMID DNA PBSI-COV-UB, WHICH ENSURES THE EXPRESSION OF THE TARGET GENE, AND AN ARTIFICIAL POLYEPITOPE BSI-COV-UB IMMUNOGEN PROTEIN CONTAINING UBIQUITIN AND EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2-SPECIFIC T-CELL IMMUNITY | 2023 |
|
RU2806590C1 |
| INTEGRATIVE PLASMID VECTOR pVEAL3-RBDdel, PROVIDING SYNTHESIS AND SECRETION OF RECOMBINANT PROTEIN OF RECEPTOR-BINDING DOMAIN RBDdelta OF CORONAVIRUS SARS-CoV-2 IN MAMMALIAN CELLS, RECOMBINANT CELL LINE STRAIN CHO-K1-RBDdelta AND RECOMBINANT PROTEIN RBDdelta SARS-CoV-2 PRODUCED BY CELL LINE STRAIN | 2023 |
|
RU2816175C1 |
| ARTIFICIAL GENE ENCODING THE BSI-COV IMMUNOGEN PROTEIN, PBSI-COV RECOMBINANT PLASMID DNA PROVIDING EXPRESSION OF THE TARGET GENE, AND AN ARTIFICIAL BSI-COV POLYEPITOPE IMMUNOGEN PROTEIN CONTAINING EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2- SPECIFIC T-CELL IMMUNITY | 2023 |
|
RU2806556C1 |
| INTEGRATIVE PLASMID VECTOR PVEAL2-S-RBD, PROVIDING THE EXPRESSION AND SECRETION OF THE RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF THE SARS-COV-2 CORONAVIRUS IN MAMMALIAN CELLS, THE RECOMBINANT CHO-K1-RBD CELL LINE STRAIN AND THE RECOMBINANT SARS-COV-2 RBD PROTEIN PRODUCED BY THE SPECIFIED STRAIN OF THE CELL LINE CHO-K1-RBD | 2021 |
|
RU2752858C1 |
| RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2802058C1 |
| RECOMBINANT RBD S-PROTEIN OF CORONAVIRUS SARS-CoV-2 AND METHOD FOR ITS PRODUCTION | 2023 |
|
RU2833839C1 |
| RECOMBINANT VACCINE AGAINST HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 | 2006 |
|
RU2317107C2 |
| METHOD FOR ENZYME IMMUNOASSAY DETERMINATION OF THE LEVEL OF ANTIGEN-RECOGNIZING B-LYMPHOCYTE RECEPTORS REPRESENTED BY MEMBRANE-SPECIFIC RBD PROTEIN SARS-COV-2, IgG ANTIBODIES | 2021 |
|
RU2760438C1 |
| ARTIFICIAL GENETIC CONSTRUCT FOR THE HETEROLOGOUS EXPRESSION OF THE S-PROTEIN RECEPTOR-BINDING DOMAIN IN A FUSED POLYPEPTIDE CHAIN WITH A NUCLEOCAPSID PROTEIN | 2022 |
|
RU2801597C1 |
